Fed Fears Hit Stocks as Trump Pushes US Chip Push
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Macro: Fed Spooks Markets
The Dow dropped over 500 points after the Fed signalled future tightening. Investor sentiment sits firmly in the "Fear" zone on the greed index. Markets are on edge. KR Kroger reports Q1 earnings today, adding another read on the US consumer.
Tech: Apple Joins Intel Manufacturing Push
Trump confirmed AAPL Apple has agreed to build chips with INTC Intel. This follows similar commitments from NVDA Nvidia and TSLA Tesla. The push for US domestic chip manufacturing is accelerating. GOOGL Google Cloud also made headlines, calling for open digital sovereignty in Europe — a sign of growing tech-geopolitical tensions across the Atlantic.
Short Interest: Squeeze Setups Building
Bears are piling into CAR Avis Budget Group. Short interest jumped to 47.5% of free float, up 7 points in a week. AI name SHAZ SharonAI saw the sharpest move — shorts surged from 11.9% to 33.2%. Borrow availability sits at just 5%. Meanwhile steel names NUE Nucor and STLD Steel Dynamics beat Q2 guidance, sending options traders rushing for calls.
Analysts: Chips Up, Software Down
MU Micron's consensus target rose to $926.85. Analysts are backing the memory chip cycle. On the other side, ADBE Adobe and CRM Salesforce both saw targets cut. AI-native rivals are squeezing legacy software players.
Insiders: Big Biotech Buy
SMMT Summit Therapeutics CEO Robert Duggan filed a $50M share purchase at $13.12. President Maky Zanganeh added $1.46M the same week. Two top executives buying together is a rare and meaningful signal.
Stocks in this article
How this article was generated
- Generated
- 18 Jun 2026, 08:50
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowORTEX Alpha signalsORTEX Alpha signalsAnalyst consensus
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.